The British Journal of Psychiatry (2007) 191: 14-22. doi: 10.1192/bjp.bp.106.028654
© 2007 The Royal College of Psychiatrists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Related articles in BJP
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Davies, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davies, L. M.

Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy

L. M. Davies, MSc and S. Lewis, MD

University of Manchester

P. B. Jones, MD, PhD

University of Cambridge

T. R. E. Barnes, MD, DSc

Imperial College, London

F. Gaughran, MD

Institute of Psychiatry, London

K. Hayhurst, MSc and A. Markwick, BA

University of Manchester

H. Lloyd, MSc

Imperial College, London, UK

the CUtLASS team

Correspondence: Linda Davies, Division of Psychiatry, University of Manchester, Rawnsley Building, MRI, Oxford Road, Manchester M13 9WL, UK. Tel: +44 (0) 161 276 5380; email: Linda.davies{at}manchester.ac.uk

Declaration of interest Funding from the Secretary of State for Health (UK). The authors have received consultancy fees, honoraria or departmental support from the pharmaceutical industry, including Novartis, BMS Otsuka, Janssen Cilag, Servier, BMS, Astra-Zeneca, Sanofi-Synthelabo, Eli Lilly and Johnson & Johnson. F.G. is related to an employee of Eli Lilly & Co.

Background There are claims that the extra costs of atypical (second-generation) antipsychotic drugs over conventional (first-generation) drugs are offset by improved health-related quality of life.

Aims To determine the relative costs and value of treatment with conventional or atypical antipsychotics in people with schizophrenia.

Method Cost-effectiveness acceptability analysis integrated clinical and economic randomised controlled trial data of conventional and atypical antipsychotics in routine practice.

Results Conventional antipsychotics had lower costs and higher quality-adjusted life-years (QALYs) than atypical antipsychotics and were more than 50% likely to be cost-effective.

Conclusions The primary and sensitivity analyses indicated that conventional antipsychotics may be cost-saving and associated with a gain in QALYs compared with atypical antipsychotics.


Related articles in BJP:

From the Editor's desk
Peter Tyrer
BJP 2007 191: 96. [Full Text]  

Highlights of this issue
Sukhwinder S. Shergill
BJP 2007 191: A2. [Full Text]  



This article has been cited by other articles:


Home page
 Schizophr BullHome page
J. Parks, A. Radke, G. Parker, M.-E. Foti, R. Eilers, M. Diamond, D. Svendsen, and R. Tandon
Principles of Antipsychotic Prescribing for Policy Makers, Circa 2008. Translating Knowledge to Promote Individualized Treatment
Schizophr Bull, September 1, 2009; 35(5): 931 - 936.
[Abstract] [Full Text] [PDF]

Home page
 Health Aff (Millwood)Home page
R. A. Rosenheck and M. J. Sernyak
Developing A Policy For Second-Generation Antipsychotic Drugs
Health Aff., September 1, 2009; 28(5): w782 - w793.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
G. C. Alexander and R. S. Stafford
Does Comparative Effectiveness Have a Comparative Edge?
JAMA, June 17, 2009; 301(23): 2488 - 2490.
[Full Text] [PDF]

Home page
 Evid. Based Ment. HealthHome page
B. Barrett and S. Byford
Economic evaluations in evidence based healthcare
Evid. Based Ment. Health, May 1, 2009; 12(2): 36 - 39.
[Full Text] [PDF]

Home page
 Evid. Based Ment. HealthHome page
P. Tyrer
So careless of the single trial
Evid. Based Ment. Health, August 1, 2008; 11(3): 65 - 66.
[Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
J. Scott
Cognitive-behavioural therapy for severe mental disorders: back to the future?
The British Journal of Psychiatry, June 1, 2008; 192(6): 401 - 403.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
P. Tyrer
From the Editor's desk
The British Journal of Psychiatry, June 1, 2008; 192(6): 482 - 482.
[Full Text] [PDF]

Home page
 Psychiatr. Serv.Home page
M. E. Domino and M. S. Swartz
Who Are the New Users of Antipsychotic Medications?
Psychiatr Serv, May 1, 2008; 59(5): 507 - 514.
[Abstract] [Full Text] [PDF]

Home page
 Psychiatr. Serv.Home page
R. A. Rosenheck, D. L. Leslie, and J. A. Doshi
Second-Generation Antipsychotics: Cost-Effectiveness, Policy Options, and Political Decision Making
Psychiatr Serv, May 1, 2008; 59(5): 515 - 520.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
S. Lewis and J. Lieberman
CATIE and CUtLASS: can we handle the truth?
The British Journal of Psychiatry, March 1, 2008; 192(3): 161 - 163.
[Abstract] [Full Text] [PDF]

eLetters:

Read all eLetters

Terminology - Cost effectiveness or Cost Utility analysis
Rajeev Krishnadas
BJP Online, 15 Aug 2007 [Full text]